Takeda (ADR)
Develops prescription medicines across gastrointestinal disease, rare disease, plasma therapies, oncology, neuroscience, and vaccines.
Something off on this page? Send us feedback.
Profile
Sells prescription medicines led by ENTYVIO and immunoglobulin therapies across six global business areas. Operates as one reportable segment, with major commercial activity spanning the United States, Europe, Japan, China, and other markets.
Develops and markets prescription medicines across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, vaccines, and other products. ENTYVIO is the largest product, while immunoglobulin brands form another major franchise.
Operates globally, with commercial activity across the United States, Europe, Japan, China, and other markets. Research, manufacturing, licensing, and specialized commercialization support a portfolio assembled through internal development and the Millennium, Nycomed, and Shire acquisitions.
Executes around established specialty franchises while preparing late-stage candidates for regulatory submission and launch. Revenue remains exposed to patent expiry, as VYVANSE's loss of exclusivity has reduced sales, and future product transitions depend on regulatory approvals and commercial execution. The group reports as one operating segment, and each NYSE ADS represents half of a Tokyo-listed ordinary share.
Company facts
Key statistics
Year to date +15.4% · Average volume (30d) 3.4M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q1 FY26 | $0.17 | $0.23 | +33.2% | $7.13B | $7.66B | +7.4% | −2.82% |
| May 13, 2026Q4 FY25 | $0.21 | $0.28 | +33.3% | $7.14B | $6.92B | −3.0% | −0.06% |
| Jan 29, 2026Q3 FY25 | $0.55 | $0.48 | −12.7% | $7.54B | $7.73B | +2.5% | +0.35% |
| Oct 30, 2025Q2 FY25 | $0.44 | $0.44 | 0.0% | $7.48B | $7.42B | −0.9% | +1.59% |
Financial highlights
| 12 quarters | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.58B | $6.91B | $6.95B | $7.58B | $6.96B | $7.62B | |
| Gross profit | $4.19B | $4.51B | $4.58B | $4.13B | $3.40B | $5.08B | |
| Operating income | −$468.0M | $1.15B | $431.1M | $1.21B | $297.0M | $1.26B | |
| Net income | −$644.8M | $776.2M | −$73.7M | $659.2M | −$154.7M | $707.2M | |
| Diluted EPS | −$0.20 | $0.24 | −$0.02 | $0.21 | −$0.05 | $0.22 | |
| Gross margin | 63.7% | 65.2% | 65.8% | 54.4% | 48.8% | 66.7% | |
| Operating margin | -7.1% | 16.7% | 6.2% | 16.0% | 4.3% | 16.5% |
Fiscal years (4-quarter sums)FY21 $22.30B · FY22 $25.16B · FY23 $26.64B · FY24 $28.62B · FY25 $28.41B
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $3.30B · Total debt $30.86B · Total assets $97.86B · Shareholders' equity $47.22B
Dividends
Last cut to $0.3083 from $0.3221 in Mar 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Mar 31, 2026 | Mar 31 | Jul 6 | $0.3083 | cut from $0.3221 |
| Sep 30, 2025 | Sep 30 | Dec 11 | $0.3221 | raised from $0.276 |
| Mar 31, 2025 | Mar 31 | Jul 7 | $0.276 | cut from $0.3261 |
| Sep 30, 2024 | Sep 30 | Dec 12 | $0.3261 | raised from $0.2922 |
| Mar 27, 2024 | Mar 28 | Jul 8 | $0.2922 | cut from $0.3191 |
| Sep 28, 2023 | Sep 29 | Dec 11 | $0.3191 | raised from $0.31 |
| Mar 30, 2023 | Mar 31 | Jul 10 | $0.31 | cut from $0.3296 |
| Sep 29, 2022 | Sep 30 | Dec 12 | $0.3296 | cut from $0.3301 |
Ownership
Shares outstanding 3.18B · Float 3.16B · 99.2% free float
Insiders — filings are in the shares behind the receipt.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Capital Research Global Investors | 19.30M | 0.61% | 13F | Aug 12, 2026 |
| FMR LLC | 9.60M | 0.30% | 13F | Aug 13, 2026 |
| Morgan Stanley | 6.99M | 0.22% | 13F | Aug 13, 2026 |
| Adage Capital Partners GP, L.L.C. | 6.05M | 0.19% | 13F | Aug 14, 2026 |
| Goldman Sachs Group Inc | 5.13M | 0.16% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Andrew Stewart Plump | director, officer: President, R&D | −19,651 | $18.49 |
| Aug 18, 2026 | Nicola Deidre Petal Greenway | officer: Chief Human Resources Officer | −12,980 | $18.11 |
| Aug 10, 2026 | Rhonda Janice Pacheco | officer: President, U.S. Business Unit | −16,901 | $17.10 |
| Aug 10, 2026 | Ramy Riad Ahmed Ibrahim | officer: President, PDT BU | −7,277 | $17.10 |
| Aug 10, 2026 | Awny Samaan Botros Farajallah | officer: Chief Medical Officer | −14,006 | $17.10 |
Peers
- AbbVie
Leading IBD overlap across Crohn's disease and ulcerative colitis
- Grifols (ADR)
Direct plasma-medicine rival in immunoglobulin and albumin
- Johnson & Johnson
Biologic competition in Crohn's disease and ulcerative colitis
- Eli Lilly
IL-23 competition in ulcerative colitis and Crohn's disease
- Pfizer
Focused overlap in ulcerative colitis and hemophilia prophylaxis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Grifols (ADR) | $7.69 | 0.00% | $6.51B | 9.9 | — | 0.9 | −4.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 36.9 | 19.6 | 6.6 | +6.6% |